Kezar changes CEOs, lays off 41% of staff and halts preclinical R&D to extend cash runway
Kezar Life Sciences, a 2015 spinout from Amgen, is laying off 41% of its workforce and pausing all preclinical R&D in a bid to extend its cash runway into late 2026 and move select clinical programs forward, the biotech said Tuesday.
There are also several executive shakeups: Kezar said co-founder John Fowler will resign as CEO on Nov. 7 and former president and CSO Christopher Kirk will take over as CEO. CMO Noreen Henig is resigning on Oct. 6 and Zung To, the senior VP of clinical development operations, will take over trial execution and development operations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.